Orexigen Therapeutics (OREX)
Orexigen Therapeutics SG&A Expense: 4.512M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OREX SG&A Expense Rankings
| Overall | 80th percentile | 816 of 4195 |
| Sector | 63rd percentile | 180 of 487 in Healthcare |
| Industry | 64th percentile | 14 of 39 in Drug Manufacturers - Other |
OREX SG&A Expense Range, Past 5 Years
| Minimum | 2.347M | Jun 2007 |
| Maximum | 6.759M | Mar 2011 |
| Average | 4.532M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these OREX related companies
OREX News
Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
May 31, 7:30AM PR Newswire
May 31, 7:30AM PR Newswire
I've sold $VRTX right after the big jump and I won't buy above $40. I'll wait for $36 again, while I'm holding $AMRN, $DNDN & $OREX :-)
about 12 hours ago by mitrado
about 12 hours ago by mitrado
$ARNA rebounds after share offering last week at $5.50 $OREX $VVUS http://stks.co/3vPY
about 10 days ago by EPS_MomentuM
about 10 days ago by EPS_MomentuM
RT @Bleedblue: RT @newkidontheblock FDA follows Adcom rec 80 percent. $orex anyone? Was the 20% it DOES happen.
about 16 days ago by DutchFanBoy
about 16 days ago by DutchFanBoy
$ARNA close above 7$ will be very bullish as market wants a turn around Tuesday $VVUS $OREX $$
about 16 days ago by peterumble
about 16 days ago by peterumble
$ARNA looks stronger day by day means more upside to come yet, a good day will break 8$ this week $VVUS $OREX $$
about 16 days ago by peterumble
about 16 days ago by peterumble
@Bleedblue don't know about dates $orex i do TA mostly very little biotech $study but have a hunch from what i've read it is safer of the 2
about 17 days ago by Good2go
about 17 days ago by Good2go
@Bleedblue agree & the reason that $orex will follow $arna & 1 day possibly have the preferred drug (fda willing that is).
about 17 days ago by Good2go
about 17 days ago by Good2go
@DrNick This is strange, seeing $OREX only has two products in the pipeline... Kind of early move, eh!? ;-)
about 17 days ago by mitrado
about 17 days ago by mitrado
@DrNick $orex nice, thanks for the link. bought some today. not in $arna
about 17 days ago by Good2go
about 17 days ago by Good2go
Arena and Orexigen Compete to Bring First Weight Loss Drug to Market in Nearly 13 Years
May 14, 8:20AM Marketwire
May 14, 8:20AM Marketwire
Bank of America: Key Takeaways from Orexigen Therapeutics' Management Meetings
Apr 11, 10:27AM Benzinga
Apr 11, 10:27AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OREX | 3.345 | -0.07 | -2.19% | 231.67M |
| SWX | 41.96 | +0.22 | +0.53% | 1.924B |
| SWU | 117.64 | +0.51 | +0.44% | |
| SWS | 5.71 | -0.05 | -0.87% | 187.83M |
| SWN | 28.04 | -0.10 | -0.36% | 9.822B |
| SWM | 66.40 | -0.25 | -0.38% | 1.062B |
| SRLS | 4.01 | +0.00 | +0.00% | 80.64M |
| SRI | 7.06 | +0.11 | +1.58% | 195.50M |
| SREV | 11.97 | -0.07 | -0.58% | 891.92M |
| SRE | 65.08 | +0.53 | +0.82% | 15.54B |
